Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Hypomethylating agent with venetoclax versus hypomethylating agent alone in frontline management of myelodysplastic syndrome - impact of subgroups on clinical outcomes

Blood (2025) 146 (Supplement 1): 239.

https://doi.org/10.1182/blood-2025-239

Published: 2025

Journal Articles

Axatilimab in combination with ruxolitinib in patients with newly diagnosed chronic graft-versus-host disease: Interim safety analysis of a phase 2, randomized study

Robert Zeiser, Annie Im, Albert Assad, Maureen Bleam, Hongfei Li, Amandeep Salhotra

Blood (2025) 146 (Supplement 1): 6012.

https://doi.org/10.1182/blood-2025-6012

Published: 2025

Journal Articles

Hairy cell leukemia treatment strategies: A real-world multicenter experience

James Fradin, Lisa Rein, Aniko Szabo, Karen-Sue Carlson, Talha Badar, Troy Holden, Shiv Shah, Annie Im, Anand Patel, Ehab Atallah

Blood (2025) 146 (Supplement 1): 1802.

https://doi.org/10.1182/blood-2025-1802

Published: 2025

Journal Articles

Evolutionary divergence of polymorphic HLA residues predicts clinical outcomes after haploidentical stem cell transplantation in patients with AML

Blood (2025) 146 (Supplement 1): 512.

https://doi.org/10.1182/blood-2025-512

Published: 2025

Journal Articles

Real-world practice patterns of IDH inhibitors and outcomes of on-label IDH inhibitor use for Acute Myeloid Leukemia in the United States

Blood (2025) 146 (Supplement 1): 1614.

https://doi.org/10.1182/blood-2025-1614

Published: 2025

Journal Articles

Myeloid malignancies molecular analysis for therapy choice (myeloMATCH): Rapid availability of clinical, pathologic and molecular features for treatment assignment in the first 550 patients.

Blood (2025) 146 (Supplement 1): 5279.

https://doi.org/10.1182/blood-2025-5279

Published: 2025

Journal Articles

Impact of Time from Diagnosis to Treatment on Outcomes of Adults with AML Treated with HMA and Venetoclax: A US-Based, Multi-Center, Real-World, Retrospective Analysis from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Samuel J. Yates, Julian J. Weiss, Abigail Sneider, Emily Geramita, Guru Subramanian Guru Murthy, Talha Badar, Annie Im, Chenyu Lin, Wei Cheng, Eric S. Winer, Yasmin Abaza, Mark R. Litzow, Ehab L. Atallah, Alok Swaroop, Anand Ashwin Patel, Rory M. Shallis

Blood (2024) 144 (Supplement 1): 447.

https://doi.org/10.1182/blood-2024-207116

Published: 2024

Journal Articles

Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome - a Multicenter Retrospective Analysis

Blood (2024) 144 (Supplement 1): 3206.

https://doi.org/10.1182/blood-2024-211623

Published: 2024

Journal Articles

Outcomes of Patients Receiving Intensive Therapy for Acute Myeloid Leukemia Relapsed after/Refractory to Frontline Less-Intensive Therapy

Rohan Achar, Benjamin J. McCormick, Emily Dworkin, Emily Geramita, Annie Im, Anand Ashwin Patel, Talha Badar, Rory M. Shallis

Blood (2023) 142 (Supplement 1): 5859.

https://doi.org/10.1182/blood-2023-179336

Published: 2023

Journal Articles

Janus Kinase (JAK) 1 Inhibition Results in Significant Changes in Serum Proteins and Peripheral T-Cell Populations That Correlated with Clinical Scores in Chronic Graft Versus Host Disease (GVHD) Patients (an Analysis from GRAVITAS-309)

Michael Pratta, Angelina Volkova, Maureen Bleam, Rodica Morariu-Zamfir, Beth Rumberger, Stephen Douglass, Susan H. Smith, Valkal Bhatt, John Galvin, Annie Im, Sophie Paczesny, Kirk R. Schultz, Steven Z. Pavletic

Blood (2023) 142 (Supplement 1): 2197.

https://doi.org/10.1182/blood-2023-174955

Published: 2023

Journal Articles

Outcomes of Adults Treated with a Hypomethylating Agent Plus Venetoclax for Relapsed/Refractory Acute Myeloid Leukemia: A Multicenter Retrospective Study

Emily Geramita, Hong Wang, Melissa Bastacky, Jessica Cohen, Rory Michael Shallis, Talha Badar, Mark R. Litzow, Annie Im

Blood (2022) 140 (Supplement 1): 6187–6188.

https://doi.org/10.1182/blood-2022-170647

Published: 2022

Journal Articles

Itacitinib and Corticosteroids As Initial Treatment for Chronic Graft-Versus-Host Disease: Phase 1/2 Results from Gravitas-309

Annie Im, Daniel Wolff, Corey Cutler, Robert Zeiser, Nirav N. Shah, Ming Tony Tan, Jaime Sanz, Haris Ali, Giuseppe Milone, Arjun D. Law, Domenico Russo, Eva-Maria Wagner, Olga Ivanova, Kevin Hou, Maureen Bleam, Rodica Morariu-Zamfir, Steven Z Pavletic

Blood (2022) 140 (Supplement 1): 1870–1871.

https://doi.org/10.1182/blood-2022-169605

Published: 2022

Journal Articles

Trial-in-Progress: A Phase 2 Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Acute Myeloid Leukemia That Persisted after the 1 st Induction Regimen

Konstantinos Lontos, Robert L. Redner, Mounzer Agha, Anastasios Raptis, Jing-Zhou Hou, Rafic J. Farah, Annie Im, Kathleen Dorritie, Alison R. Sehgal, James M. Rossetti, Daniel Normolle, Michael M. Boyiadzis

Blood (2022) 140 (Supplement 1): 6145–6146.

https://doi.org/10.1182/blood-2022-156468

Published: 2022

Journal Articles

Feasibility and Safety of Outpatient Hypomethylating Agent (HMA) + Venetoclax (Ven) Initiation +/- Ramp-up for Patients (pts) with Newly-Diagnosed Acute Myeloid Leukemia (AML)

Rory Michael Shallis, Julian Weiss, Eric S. Winer, Talha Badar, Alok Swaroop, Peter Doukas, Emily Geramita, Henry Le, Sonal Agarwal, Man Yee Merl, Annie Im, Yasmin Abaza, Mark R. Litzow, Nikolai A. Podoltsev

Blood (2022) 140 (Supplement 1): 8921–8922.

https://doi.org/10.1182/blood-2022-165446

Published: 2022

Journal Articles

Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study

Blood (2021) 138 (22): 2278–2289.

https://doi.org/10.1182/blood.2021012021

Published: 2021

Includes: Supplemental data

Journal Articles

Effects of Alvelestat, an Oral Neutrophil Elastase Inhibitor, on Elevated Elastase and Collagen Turnover Biomarkers in Patients with Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation

Annie Im, Jacqueline Parkin, Noa G. Holtzman, William Moore, Lauren M. Curtis, Cody Peer, William D. Figg, Sr., Jeremy J. Rose, Laura Parsons-Wandell, Frances T. Hakim, Steven Z. Pavletic

Blood (2021) 138 (Supplement 1): 1815.

https://doi.org/10.1182/blood-2021-151324

Published: 2021

Journal Articles

Pretreatment Next-Generation Sequencing Is Associated with Response to Induction Chemotherapy in Patients Newly Diagnosed with Acute Myeloid Leukemia

Anastasia Tsagianni, MD, Konstantinos Lontos, MD, Mounzer Agha, MD, Anastasios Raptis, MD, Jing-Zhou Hou, MD PhD, Rafic J. Farah, MD, Robert L. Redner, MD, Annie Im, MD, Kathleen A. Dorritie, MD, Alison R. Sehgal, MD, James M. Rossetti, DO, Melissa Saul, MS, William Gooding, MS, Michael Boyiadzis, MD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-138561

Published: 2020

Journal Articles

Efficacy and Safety of Baricitinib in Refractory Chronic Graft-Versus-Host Disease (cGVHD): Preliminary Analysis Results of a Phase 1/2 Study

Noa G. Holtzman, MD, Annie Im, MD, Alen Ostojic, MD, Lauren M. Curtis, MD, Laura Parsons-Wandell, RN, Jeannette Nashed, BSN MSN CRNP, Cody Peer, PhD, William D. Figg, Sr., PharmD, M. Teresa Magone, MD, Edward W Cowen, MD, Jacqueline W Mays, DDS, PhD, Frances T. Hakim, PhD, Jeremy J. Rose, MS, Marie C Pouzelles, PhD, Naomi Taylor, MD PhD, Steven Z. Pavletic, MD MS

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-140392

Published: 2020

Journal Articles

Phase 1 Study of Alvelestat, an Oral Neutrophil Elastase Inhibitor, in Patients with Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation

Annie Im, MD, Noa G. Holtzman, MD, Lauren M. Curtis, MD, Laura Parsons-Wandell, RN, Jeannette Nashed, BSN MSN CRNP, Cody Peer, PhD, William D. Figg, PhD, Amisha Barochia, MBBS, MHS, Jeremy J. Rose, MS, Frances T. Hakim, PhD, Steven Z. Pavletic, MD MS

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-140481

Published: 2020

Journal Articles

Accrual Barriers and Detection of Early Toxicity Signal in Older Less-Fit Patients Treated with Azacitidine and Nivolumab for Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) in the SWOG 1612 Platform Randomized Phase II/III Clinical Trial

Annette E. Hay, Sarit Assouline, MD, Roland B. Walter, MD PhD MS, Richard F. Little, MD MPH, Anna Moseley, M.S., Sperling M Gail, MPH, CHES, Annie Im, MD, James M. Foran, MD, Jerald P. Radich, MD, Min Fang, MD PhD, Megan Othus, PhD, Harry P. Erba, MD PhD, Laura C. Michaelis, MD

Blood (2019) 134 (Supplement_1): 3905.

https://doi.org/10.1182/blood-2019-124320

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Hypomethylating agent with venetoclax versus hypomethylating agent alone in frontline management of myelodysplastic syndrome - impact of subgroups on clinical outcomes

Axatilimab in combination with ruxolitinib in patients with newly diagnosed chronic graft-versus-host disease: Interim safety analysis of a phase 2, randomized study

Hairy cell leukemia treatment strategies: A real-world multicenter experience

Evolutionary divergence of polymorphic HLA residues predicts clinical outcomes after haploidentical stem cell transplantation in patients with AML

Real-world practice patterns of IDH inhibitors and outcomes of on-label IDH inhibitor use for Acute Myeloid Leukemia in the United States

Myeloid malignancies molecular analysis for therapy choice (myeloMATCH): Rapid availability of clinical, pathologic and molecular features for treatment assignment in the first 550 patients.

Impact of Time from Diagnosis to Treatment on Outcomes of Adults with AML Treated with HMA and Venetoclax: A US-Based, Multi-Center, Real-World, Retrospective Analysis from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome - a Multicenter Retrospective Analysis

Outcomes of Patients Receiving Intensive Therapy for Acute Myeloid Leukemia Relapsed after/Refractory to Frontline Less-Intensive Therapy

Janus Kinase (JAK) 1 Inhibition Results in Significant Changes in Serum Proteins and Peripheral T-Cell Populations That Correlated with Clinical Scores in Chronic Graft Versus Host Disease (GVHD) Patients (an Analysis from GRAVITAS-309)

Outcomes of Adults Treated with a Hypomethylating Agent Plus Venetoclax for Relapsed/Refractory Acute Myeloid Leukemia: A Multicenter Retrospective Study

Itacitinib and Corticosteroids As Initial Treatment for Chronic Graft-Versus-Host Disease: Phase 1/2 Results from Gravitas-309

Trial-in-Progress: A Phase 2 Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Acute Myeloid Leukemia That Persisted after the 1 st Induction Regimen

Feasibility and Safety of Outpatient Hypomethylating Agent (HMA) + Venetoclax (Ven) Initiation +/- Ramp-up for Patients (pts) with Newly-Diagnosed Acute Myeloid Leukemia (AML)

Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study

Effects of Alvelestat, an Oral Neutrophil Elastase Inhibitor, on Elevated Elastase and Collagen Turnover Biomarkers in Patients with Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation

Pretreatment Next-Generation Sequencing Is Associated with Response to Induction Chemotherapy in Patients Newly Diagnosed with Acute Myeloid Leukemia

Efficacy and Safety of Baricitinib in Refractory Chronic Graft-Versus-Host Disease (cGVHD): Preliminary Analysis Results of a Phase 1/2 Study

Phase 1 Study of Alvelestat, an Oral Neutrophil Elastase Inhibitor, in Patients with Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation

Accrual Barriers and Detection of Early Toxicity Signal in Older Less-Fit Patients Treated with Azacitidine and Nivolumab for Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) in the SWOG 1612 Platform Randomized Phase II/III Clinical Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only